Invention Grant
- Patent Title: Beta-2-glycoprotein 1 derived peptide and use thereof for treating antiphospholipid syndrome
-
Application No.: US16615460Application Date: 2018-05-23
-
Publication No.: US11919939B2Publication Date: 2024-03-05
- Inventor: Karim Brandt
- Applicant: Université de Genéve
- Applicant Address: CH Geneva
- Assignee: Université de Genève
- Current Assignee: Université de Genève
- Current Assignee Address: CH Geneva
- Agency: Harness Dickey & Pierce P.L.C.
- Priority: EP 172584 2017.05.23
- International Application: PCT/EP2018/063439 2018.05.23
- International Announcement: WO2018/215506A 2018.11.29
- Date entered country: 2019-11-21
- Main IPC: C07K14/74
- IPC: C07K14/74 ; C07K7/06 ; G01N33/564 ; A61K38/00
Abstract:
The invention provides an isolated peptide containing a motif that binds antiphospholipid antibodies (aPLA) and that is recognized by CD4+ T cells that are able to induce production of antiphospholipid antibodies (aPLA). The present invention further provides methods for detection of aPLA and CD4+ T cells able to induce production of aPLA. The present invention also provides methods for treating the antiphospholipid syndrome (APS).
Public/Granted literature
- US20200172596A1 BETA-2-GLYCOPROTEIN 1 DERIVED PEPTIDE AND USE THEREOF FOR TREATING ANTIPHOSPHOLIPID SYNDROME Public/Granted day:2020-06-04
Information query
